A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

NCT04444167 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: AK104
DRUG: Lenvatinib

Sponsor

Akeso

Collaborators

[object Object]